We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Global prevalance of obesity
- Current and coming anti-obesity agents
- Bariatric surgery - the only successful therapy
- Skin redundancy after massive weight loss
- The gut hormones
- Ghrelin
- Energy intake after administration of ghrelin
- Meal intake after ghrelin infusion in cancer patients
- Why do you feel less hungry after a meal?
- Gut hormones: three types of satiety action
- Peptide YY (PYY) (1)
- GI tract distribution of PYY
- Post prandial secretion of PYY
- Peptide YY (PYY) (2)
- PYY levels in different patients
- PYY levels elevated post bypass surgery
- Effect of PYY3-36 on food intake (1)
- Effect of PYY3-36 on food intake (2)
- Effect of PYY3-36 on cumulative 24h food intake
- PYY3-36 hunger scores
- PYY3-36 on ghrelin
- PYY levels during saline infusion
- Meal calories and PYY blood level in fat and thin
- Plasma PYY levels at each infusion dose
- Percent reduction in calories after PYY infusion
- Food intake increased after PYY
- Three characteristics of PYY3-36 on appetite
- Glucagon-like peptide 1
- The effect of chronic GLP-1 on body weight
- Exendin stimulates food intake in satiated rats
- 24 week trial of exenatide against insulin glargine
- 82 weeks follow up
- Oxyntomodulin (1)
- Oxyntomodulin (2)
- Chronic IP administration of oxyntomodulin
- Effect of oxyntomodulin on food intake in humans
- Four week oxyntomodulin trial
- Trial protocol
- Type of administration
- Oxyntomodulin effect on weight loss
- Oxyntomodulin effect on leptin levels
- Oxyntomodulin effect on calorie intake
- Oxyntomodulin effect on insulin levels
- Effect on energy expenditure
- Oxyntomodulin and energy balance
- Design of oxyntomodulin analogues
- Oxyntomodulin analogue 23/36
- Effect of oxyntomodulin analogue on weight loss
- Oxyntomodulin versus GLP-1
- Manganese enhanced MRI
- Ghrelin manganese enhanced MRI
- GLP1 against oxyntomodulin
- Buffet meal energy intake
- Human pancreatic polypeptide (1)
- Human pancreatic polypeptide (2)
- Effect of hPP analogues on food intake
- Effect of PYY, hPP or combination on food intake
- Peptides as drugs - better targeted
- Rimonabant and oxyntomodulin are additive
- Concluding remarks
Topics Covered
- Anti-obesity agents
- Bariatric surgery
- The gut hormones
- Ghrelin
- Energy intake free-choice meal
- Meal intake after Ghrelin infusion
- Why do you feel less hungry after a meal?
- Three types of satiety action
- Peptide YY (PYY)
- GI tract distribution of PYY
- Post-prandial secretion of PYY
- Effect of PYY on food intake
- Glucagon-like peptide 1
- The effect of chronic GLP-1 on body weight
- Oxyntomodulin
- Leptin change
- Human pancreatic polypeptide
- Peptides as drugs: better targeted
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Bloom, S. (2009, March 31). Gastrointestinal peptides and food intake regulation [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 5, 2024, from https://doi.org/10.69645/OJXA9457.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Sir Stephen Bloom, Grant/Research Support (Principal Investigator): Medical Research Council